Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial

Breast Cancer Research, 05/04/2012

p53 truncating mutations were uncommon but associated with poor prognosis. No significant predictive role for p53 status was detected.

Print Article Summary